` AEMD (Aethlon Medical Inc) vs S&P 500 Comparison - Alpha Spread

AEMD
vs
S&P 500

Over the past 12 months, AEMD has underperformed S&P 500, delivering a return of -94% compared to the S&P 500's +14% growth.

Stocks Performance
AEMD vs S&P 500

Loading
AEMD
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
AEMD vs S&P 500

Loading
AEMD
S&P 500
Difference
www.alphaspread.com

Performance By Year
AEMD vs S&P 500

Loading
AEMD
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Aethlon Medical Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Aethlon Medical Inc
Glance View

Market Cap
2.2m USD
Industry
Health Care

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.

AEMD Intrinsic Value
7.7 USD
Undervaluation 63%
Intrinsic Value
Price
Back to Top